Tandem Diabetes Care, Inc. Income (Loss) from Equity Method Investments
Tandem Diabetes Care, Inc. (TNDM) reported Income (Loss) from Equity Method Investments of -$5.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-08-06
- Tandem Diabetes Care, Inc. income (loss) from equity method investments for the quarter ending 2026-06-30 was -$5.64M.
- Tandem Diabetes Care, Inc. income (loss) from equity method investments for the quarter ending 2026-03-31 was -$3.87M.
- Tandem Diabetes Care, Inc. income (loss) from equity method investments for the quarter ending 2025-12-31 was -$4.55M.
- Tandem Diabetes Care, Inc. income (loss) from equity method investments for the quarter ending 2025-09-30 was -$2.72M.
- Tandem Diabetes Care, Inc. income (loss) from equity method investments for fiscal 2025 was -$14.19M.
- Tandem Diabetes Care, Inc. income (loss) from equity method investments for fiscal 2024 was -$2.05M.
- Tandem Diabetes Care, Inc. income (loss) from equity method investments for fiscal 2023 was $0.00.
- Tandem Diabetes Care, Inc. income (loss) from equity method investments for fiscal 2022 was $0.00.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.64M 10-Q · filed 2026-08-06 | -$9.51M 10-Q · filed 2026-08-06 | -$14.06M derived: sum of 3 quarters · filed 2026-08-06 | -$16.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$3.87M 10-Q · filed 2026-05-07 | -$8.42M derived: sum of 2 quarters · filed 2026-05-07 | -$11.14M derived: sum of 3 quarters · filed 2026-05-07 | -$14.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$7.28M derived: sum of 2 quarters · filed 2026-02-19 | -$10.65M derived: sum of 3 quarters · filed 2026-08-06 | -$14.19M 10-K · filed 2026-02-19 |
| 2025-09-30 | -$2.72M 10-Q · filed 2025-11-06 | -$6.10M derived: sum of 2 quarters · filed 2026-08-06 | -$9.64M 10-Q · filed 2025-11-06 | -$11.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$3.38M 10-Q · filed 2026-08-06 | -$6.92M 10-Q · filed 2026-08-06 | -$8.97M derived: sum of 3 quarters · filed 2026-08-06 | -$8.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$3.54M 10-Q · filed 2026-05-07 | -$5.59M derived: sum of 2 quarters · filed 2026-05-07 | -$5.59M derived: sum of 3 quarters · filed 2026-05-07 | -$5.59M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$2.05M derived: sum of 2 quarters · filed 2026-02-19 | -$2.05M derived: sum of 3 quarters · filed 2026-02-19 | -$2.05M 10-K · filed 2026-02-19 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-04-30 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-19 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |